EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study

Chao-Yuan Huang, Chi-Ping Huang, Yu-Yi Huang, Steven Kuan-Hua Huang, Kevin Lu iD, William Ji-Sien Huang, En Meng, Shu-Pin Huang, Ming-Yang Lee, Frank Chen, See-Tong Pang

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35040 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Chao-Yuan Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium, Bone Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several life‐prolonging therapies for metastatic castration‐resistant prostate cancer (mCRPC) are available, including radium‐223 dichloride ( 223 Ra), which was approved based on phase 3 data demonstrating improved overall survival (OS) and a favorable safety profile. To date, real‐world evidence for 223 Ra use in Taiwan is from three studies of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiumBone NeoplasmsHumansMaleAgedProspective StudiesMiddle AgedAged, 80 and overTaiwanTreatment OutcomeRadioisotopes

Stichwörter der Autor:innen

RWEbone metastasismetastatic castration‐resistant prostate cancerradium‐223real‐world evidence

Substanzen

RadiumRadium-223radium Ra 223 dichlorideRadioisotopes

Autor:innen und Institutionen

  • Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Urology, China Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
  • Department of Nuclear Medicine, Koo-Foundation, Sun Yat-Sen Cancer Center, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yung Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.

ORCID-Profile: Kevin Lu

Förderung

  • Bayer

Zitieren

APA

Huang, C. Y., Huang, C. P., Huang, Y. Y., Huang, S. K., Lu, K., Huang, W. J., Meng, E., Huang, S. P., Lee, M. Y., Chen, F., & Pang, S. T. (2024). Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study. International Journal of Cancer. https://doi.org/10.1002/ijc.35040

Vancouver

Huang CY, Huang CP, Huang YY, Huang SK, Lu K, Huang WJ, et al. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study. International Journal of Cancer. 2024. doi:10.1002/ijc.35040

BibTeX
@article{Huang2024,
  author = {Huang, Chao-Yuan and Huang, Chi-Ping and Huang, Yu-Yi and Huang, Steven Kuan-Hua and Lu, Kevin and Huang, William Ji-Sien and Meng, En and Huang, Shu-Pin and Lee, Ming-Yang and Chen, Frank and Pang, See-Tong},
  title = {Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35040}
}
Kostenlos starten →